Equillium (NASDAQ: EQ)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.370 | -0.450 | -0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Equillium (NASDAQ: EQ) through any online brokerage.
Other companies in Equillium’s space includes: Orchard Therapeutics (NASDAQ:ORTX), 89bio (NASDAQ:ETNB), Galectin Therapeutics (NASDAQ:GALT), Lumos Pharma (NASDAQ:LUMO) and Bolt Biotherapeutics (NASDAQ:BOLT).
The latest price target for Equillium (NASDAQ: EQ) was reported by HC Wainwright & Co. on Thursday, March 24, 2022. The analyst firm set a price target for 15.00 expecting EQ to rise to within 12 months (a possible 610.90% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Equillium (NASDAQ: EQ) is $2.11 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Equillium.
Equillium’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Equillium.
Equillium is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.